Based on the Annexon Inc stock forecast from 1 analysts, the average analyst target price for Annexon Inc is USD 16.00 over the next 12 months. Annexon Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Annexon Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Annexon Inc’s stock price was USD 5.23. Annexon Inc’s stock price has changed by +5.66% over the past week, +2.55% over the past month and +30.42% over the last year.
No recent analyst target price found for Annexon Inc
No recent average analyst rating found for Annexon Inc
Company Overview Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Read Less
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patien...Read More
Frequently Asked Questions About Annexon Inc (ANNX) Stock
Based on ratings from 1 analysts Annexon Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANNX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ANNX is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
ANNX stock's Price/Earning ratio is -99,999.99.
Our analysis grades ANNX stock's Price / Earning ratio at A+. This means that ANNX stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ANNX may be undervalued for its sector.
The last closing price of ANNX's stock was USD 5.23.
The most recent market capitalization for ANNX is USD 0.54B.
Based on targets from 1 analysts, the average taret price for ANNX is projected at USD 16.00 over the next 12 months.
This means that ANNX's stock price may go up by +205.93% over the next 12 months.
We can't find any ETFs which contains Annexon Inc's stock.
As per our most recent records Annexon Inc has 71 Employees.
Annexon Inc's registered address is 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005.
You can get more information about it from Annexon Inc's website at https://www.annexonbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Annexon Inc (ANNX) Stock
Based on ratings from 1 analysts Annexon Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANNX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ANNX is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
ANNX stock's Price/Earning ratio is -99,999.99.
Our analysis grades ANNX stock's Price / Earning ratio at A+. This means that ANNX stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ANNX may be undervalued for its sector.
The last closing price of ANNX's stock was USD 5.23.
The most recent market capitalization for ANNX is USD 0.54B.
Based on targets from 1 analysts, the average taret price for ANNX is projected at USD 16.00 over the next 12 months.
This means that ANNX's stock price may go up by +205.93% over the next 12 months.
We can't find any ETFs which contains Annexon Inc's stock.
As per our most recent records Annexon Inc has 71 Employees.
Annexon Inc's registered address is 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005.
You can get more information about it from Annexon Inc's website at https://www.annexonbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANNX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
